Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNP-EF2K siRNA
- Development stage
- Preclinical
- Lead developer
- Orta Doğu Teknik Üniversitesi
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Parenteral
01
Overview
MNP-EF2K siRNA is a nanoparticle-formulated gene therapy consisting of magnetic nanoparticles (MNPs) incorporating small interfering RNA (siRNA) targeting eukaryotic translation elongation factor 2 kinase (eEF-2K) [1125]. Developed by researchers at the University of Texas MD Anderson Cancer Center and Middle East Technical University (METU), eEF-2K is an atypical kinase that is highly upregulated in BRCA1-mutated breast cancers, where it promotes cell survival, proliferation, and drug resistance [1125]. By silencing eEF-2K expression, MNP-EF2K siRNA inhibits tumor cell proliferation, angiogenesis, and induces apoptosis [1125]. In preclinical models of BRCA1-mutated breast cancer, systemic administration of MNP-EF2K siRNA significantly inhibits tumor growth and sensitizes cancer cells to PARP inhibitors such as olaparib [1125].
- Other names
- magnetic nanoparticle-EF2K siRNAmagnetic nanoparticle-eEF2K siRNAmagnetic nanoparticles incorporating EF2K siRNAMNP-EF2K siRNAMNP-EF-2K siRNAMNP-EF 2K siRNAMNP-eEF2K siRNAMNP-eEF-2K siRNAMNP-eEF 2K siRNA
02
Targets
EEF2K (Eukaryotic elongation factor 2 kinase)
Beyond the preview
Go deeper on MNP-EF2K siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNP-EF2K siRNA.